logo-loader
viewVolitionRx

VolitionRx and partner win $1M grant to develop lung cancer blood test

VolitionRx will receive $820,000 and Gyros Protein Technologies will get $230,000 in the form of a non-repayable Eurostars cash grant

Mesa Laboratories - VolitionRx Limited and Gyros Protein Technologies AB have been awarded more than $1 million in Europe to collaborate on developing a lung cancer blood test
The resulting blood-based test will be used for triaging individuals testing positive in Low Dose CT lung cancer screening

VolitionRx Limited (NYSEAMERICAN:VNRX) announced Thursday that it and Gyros Protein Technologies AB have been awarded more than $1 million to collaborate on developing a lung cancer blood test. 

VolitionRx will receive $820,000 (€740,000) and Gyros Protein Technologies, now part of Mesa Laboratories Inc (NASDAQ:MLAB), will get $230,000 (€206,000) in the form of a non-repayable Eurostars cash grant, according to a statement. 

The grant proceeds are to be used towards the development of novel, high sensitivity assays and a validated panel ready for regulatory trials through the combination of VolitionRx’s propriety Nu.QTM platform and Gyros Protein Technologies' Gyrolab technology. 

READ: VolitionRx unveils promising proof-of-concept data for leukemia and lymphoma tests

The resulting blood-based test will be used for triaging individuals testing positive in Low Dose CT lung cancer screening.

"This Eurostars funding will greatly assist with the development of our groundbreaking Nu.QTM technology on a new high sensitivity platform, in addition to our current ELISA plate and bead-based assays,” Marielle Herzog, research and development director with Belgian Volition SPRL, the company's Belgium-based subsidiary.

“We are very excited to yet again broaden the range of our technology platform by working with Gyros Protein Technologies, who we believe has excellent immunoassay solutions that should complement the work we are doing.”

VolitionRx and Gyros Protein Technologies will collaborate to develop 12 novel Research Use Only liquid biopsy assays based on VolitionRx's Nu.QTM immunoassays and Gyros Protein Technologies' Gyrolab platform to profile unique circulating cell-free nucleosomes. 

Combining both technologies, the assays will be supported by a new ultra-sensitive Gyrolab Bioaffy CD and Nu.QTM profiles to differentiate lung cancer from benign disease. 

Headquartered in Isnes, Belgium, VolitionRx said a validated triage panel will be developed in a prospectively collected cohort, with the goal to be ready for regulatory trials.

"Lung cancer is the leading cause of cancer death worldwide and has the lowest five-year survival rate of any cancer, with less than half of cases detected at early, treatable stages,” said Ivan Kamensky, divisional vice president of operations and research and development at Gyros Protein Technologies.

“We believe Volition's innovative biomarker panels have the potential to greatly improve the standard of care for those at high risk of lung cancer, and we are grateful to Eurostars for funding this collaborative project."

Eurostars is a European joint program, co-funded from the national budgets of 36 EUREKA countries and by the European Union through Horizon 2020. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: VolitionRx

Price: 4.17 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $171.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO highlights 'very strong assay and platform development progress'

VolitionRx Limited's (NYSEAMERICAN:VNRX) president and CEO Cameron Reynolds recaps on what he describes as a year of 'very strong progress' in assay and platform development with its Nu.Q Capture program and epigenetic toolkit Nu.Q Vet. Heading into 2020, Reynolds says the company's well...

4 days, 22 hours ago

3 min read